Gossamer Bio, Inc.

Stage 4 · Declining · week 33

As of Oct 22, 2026, Gossamer Bio is in Stage 4, the downtrend phase, now in week 33 (since Mar 5, 2026). It closed at $9.46, 96.9% below its 52-week high and below its 200-day average, which is falling.

$9.46

-5.26% today

$57.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is GOSS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S2 33w

S4 33w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 12w → S2 8w → S3 4w → S4 6w → S1 6w → S2 4w → S1 1w → S4 4w → S1 1w → S2 3w → S1 1w → S4 9w → S1 1w → S2 11w → S3 8w → S2 33w → S3 4w → S4 33w current

Total tracked: 165 weeks across 19 stage runs.

GOSS among Biotechnology531st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…531	GOSSGossamer Bio, Inc.	Stage 4 · wk 33	5	−13.9%

vs 52W High

-96.9%

$8.43 lo$303.20 hi

96.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 33

1w13w26w

Week 33, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-79.8%

200 DMA: $46.93 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.67x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.9%

-13.1%

-68.4%

YTD

-95.9%

-94.6%

Scan Membership

Breakout Watch

Latest: 2025-06-18

9 appearances in last 60 days. First seen: 2019-12-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 33 · Vol 0.67x

2026-10-21S4

Wk 32 · Vol 0.75x

2026-10-20S4

Wk 32 · Vol 0.75x

2026-10-19S4

Wk 32 · Vol 0.63x

2026-10-16S4

Wk 32 · Vol 0.61x

2026-10-15S4

Wk 32 · Vol 0.71x

2026-10-14S4

Wk 31 · Vol 1.30x

2026-10-13S4

Wk 31 · Vol 1.76x

2026-10-12S4

Wk 31 · Vol 0.56x

2026-10-09S4

Wk 31 · Vol 1.05x

2026-10-08S4

Wk 31 · Vol 0.70x

2026-10-07S4

Wk 30 · Vol 0.86x

Moving averages & range

50 DMA

$11.54

200 DMA

$46.93

52W High

$303.20

52W Low

$8.43

5D Low

$8.43

Resistance levels (recent highs)

20d High

$11.85

60d High

$16.40

120d High

$28.00

250d High

$303.20

Next resistance

+25.3%

to 20d High

Dividend Yield

0.00%

P/B -0.6

Gossamer Bio: quick answers

What stage is Gossamer Bio in?

As of Oct 22, 2026, Gossamer Bio (GOSS) is in Stage 4, the downtrend phase. It entered Stage 4 on Mar 5, 2026 and is in week 33. What the four stages mean

Is Gossamer Bio in an uptrend?

No. Gossamer Bio is in a Stage 4 downtrend. It trades 79.8% below its 200-day average, which is falling.

How far is Gossamer Bio from its 52-week high?

Gossamer Bio closed at $9.46 on Oct 22, 2026, 96.9% below its 52-week high of $303.20. Its 52-week low is $8.43.

How has Gossamer Bio performed over the past year?

As of Oct 22, 2026, Gossamer Bio is down 94.6% over the past year and down 95.9% so far in 2026.

Which sector and industry is Gossamer Bio in?

Gossamer Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.